Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02590068 · ClinicalTrials.gov registry record · NA
Effects of Chronic Viral Infection on Immune Response to Zoster Vaccination
A NA study, sponsored by Rockefeller University.
- Terminated
- Registry status
- NA
- Development phase
- 14
- Enrollment target
NCT02590068: Clinical Trial NA study, sponsored by Rockefeller University.
NCT02590068 is a NA study that was terminated before completion, run by Rockefeller University. The registered enrollment target is 14 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02590068, a NA study, was terminated before completion, sponsored by Rockefeller University.
- TERMINATED
- Registry status
- NA
- Development phase
- 14 participants
- Enrollment target
Study Summary
This study aims to identify the innate and adaptive immune response to zoster vaccination. Half of the participants will be individuals with chronic hepatitis C, while the other half with healthy volunteers.The innate immune signature elicited by Zoster vaccination will be characterized by RNA-seq analysis of pre- and post-vaccination RNA from whole blood. We will compare fold changes in gene expression profiles pre- versus post-vaccination in each individual, as well as between the two arms of the study. RNA-seq will be used to assess innate immune activation by evaluating the changes to the expression levels of interferon-stimulated genes pre- and post-vaccination. Adaptive immune response will be determined by the traditional correlates of protection used in previous Zoster clinical studies in addition to flow cytometry24. Correlates of protection include antibody response, interferon gamma production and the frequency of responder cells post- vaccination24. For antibody production, we will perform Zoster glycoprotein ELISA (gpELISA) targeting IgG/IgM. The number and frequency of responder cells will be characterized by flow cytometry.
Primary Outcome
Serum zoster antibody level would be measured by gpELISA expressed in (units/mL)
Interventions
- DRUG Zoster vaccine live
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2015-12 |
| Est. Completion | 2017-09-08 |
| Phase | NA |
Why NCT02590068 stopped before completion
NCT02590068 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 1 intervention - of which Zoster vaccine live is the first listed.
NCT02590068 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02590068 about?
NCT02590068 is a clinical study titled "Effects of Chronic Viral Infection on Immune Response to Zoster Vaccination". This study aims to identify the innate and adaptive immune response to zoster vaccination. Half of the participants will be individuals with chronic hepatitis C, while the other half with healthy volunteers.The innate immune signature elicited by Zoster vaccination will be characterized by RNA-seq a...
What is the current status of trial NCT02590068?
This trial is currently terminated. It is a NA study. The enrollment target is 14 participants. The study started on 2015-12. Estimated completion is 2017-09-08.
What interventions are being tested in trial NCT02590068?
The interventions under investigation include: Zoster vaccine live (DRUG).
Who is sponsoring clinical trial NCT02590068?
This trial is sponsored by Rockefeller University, which has 117 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02590068's enrollment target sits among peer trials
14 1909th of 2000 higher than 90 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia